| To evaluate the clinic effect of modified Shengmai San combined western medicine on angina pectoris.Methods:The China National Knowledge Infrastructure(CNKI),China Biology Medicine disc(CBMdisc),China Science Periodical Database(CSPD),Chinese Citation Database(CCD),PubMed,Cochrane Central Register of Controlled Trials(CENTRAL),and ClinicalTrial.gov were retrieved to collect randomized controlled trails(RCTs) of Shengmai san in the treatment of angina pectoris.The retrieval period was from 2000 to 2020.Cochrane risk bias assessment tool was used to evaluate the quality of included studies,and Meta-analysis was performed on the extracted data by using Revman5.3.The evidence quality evaluation of the outcome index was carried out by GRADE profiler 3.6.Results:Twenty clinical trials were screened out according to relevant criteria,including 1 962 patients.The results of Meta-analysis showed that modified Shengmai San combined western medicine(the treatment group) had a superior effect on the treatment of angina pectoris to the control group(OR=4.09,95%CI 3.20 to 5.52,P<0.000 01).The efficacy of electrocardiogram in the treatment group was better than that in the control group(OR=2.41,95%CI 1.84 to 3.17,P<0.000 01),and the efficacy of traditional Chinese medicine syndromes was better than that in the control group(OR=4.48,95%CI 2.36 to 8.50,P<0.000 01).The triacylglycerol(TG) level in the treatment group was lower than in the control group(MD=-0.80,95%CI -0.95 to -0.65,P<0.000 01),and the low-density lipoprotein cholesterin(LDL-C) level were lower than in the control group(MD=-0.81,95%CI -1.02 to -0.60,P<0.000 01).Adverse reactions in the treatment group were lower than in the control group(OR=0.12; 95%CI 0.03 to 0.46,P<0.05).Conclusion:Modified Shengmai San combined western medicine had effect had high efficacy and security in the treatment of the angina pectoris. |
